MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition

Nature Communications

Volumn 5, Issue , 2014, Pages

  Parikh, Aditya ^a   Lee, Christine ^a,b   Joseph, Peronne ^b   Marchini, Sergio ^c   Baccarini, Alessia ^a   Kolev, Valentin ^a   Romualdi, Chiara ^d   Fruscio, Robert ^e,f   Shah, Hardik ^a   Wang, Feng ^a   Mullokandov, Gavriel ^a   Fishman, David ^a   D'Incalci, Maurizio ^c   Rahaman, Jamal ^a   Kalir, Tamara ^a,f   Redline, Raymond W ^g   Brown, Brian D ^a   Narla, Goutham ^a,b,h   Difeo, Analisa ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f MaNGO Group   (Italy)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 181A; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MIRN181 MICRORNA, HUMAN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD7 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

BIOMARKER; CANCER; GENE EXPRESSION; RNA; SURVIVAL;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ADULT; AGED; CANCER STAGING; CELL MOTION; DISEASE COURSE; DRUG RESISTANCE; ENDOMETRIOID CARCINOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR INVASION;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHORYLATION; SMAD2 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84891883182     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3977     Document Type: Article

References (41)

1. Siegel, R.,Ward, E., Brawley, O. & Jemal, A. Cancer statistics. Cancer J. Clin. 61, 212-216 (2011
2. Seidman, J. D. et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum. Pathol. 35, 918-933 (2004 (Pubitemid 39037176)
3. Yang, D. et al. Intregrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23, 186-199 (2013
4. Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R. & Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39, 673-677 (2007 (Pubitemid 46676103)
5. Mateescu, B. et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 17, 1627-1635 (2011
6. Iorio, M. V. et al. microRNA signatures in human ovarian cancer. Cancer Res. 67, 8699-8707 (2007 (Pubitemid 47437445)
7. Nam, E. J. et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14, 2690-2695 (2008
8. Yang, N. et al. MicroRNA microarray identifies Let-7i as a novel biomarker anti-therapeutic target in human epithelial ovarian cancer. Cancer Res. 68, 10307-10314 (2008
9. Dahiya, N. & Morin, P. J. MicroRNAs in ovarian carcinomas. Endocr. Relat. Cancer 17, F77-F89 (2010
10. Dahiya, N. et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 18, e2436 (2008
11. Bell, D. et al. The Cancer Genome Atlas. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
12. Li, X. et al. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ. 19, 378-386 (2012
13. Yang, C. C. et al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J. Oral. Pathol. Med. 40, 397-404 (2011
14. Ji, J. et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50, 472-480 (2009
15. Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L. & Struhl, K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 439-506 (2010
16. Taylor, M. A., Sossey-Alaoui, K., Thompson, C. L., Danielpour, D. & Schiemann, W. B. TGF-b upregulates miR-181a expression to promote breast cancer metastasis. J. Clin. Invest. 123, 150-163 (2013
17. Corson, T. W. et al. Kif14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24, 4741-4753 (2005 (Pubitemid 41076292)
18. Therlault, B. L. & Nachtigal, N. W. Human ovarian cancer cell morphology, motility, and proliferation are differentially influenced by autocrine TGFb superfamily signalling. Cancer Lett. 313, 108-121 (2011
19. Navon, R. et al. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 11, e8003 (2009
20. Haraguchi, T., Ozaki, Y. & Iba, H. Vectors expressing efficient RNA decoys achieve long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 6, e43 (2009
21. Baccarini, A. et al. Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells. Curr. Biol. 21, 369-376 (2011
22. Guo, H., Ingolia, N., Weissman, J. & Bartel, D. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010
23. Zeisberg, M. & Kalluri, R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J. Mol. Med. (Berl) 82, 175-181 (2004 (Pubitemid 38392167)
24. Pardali, K. & Moustakas, A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 1, 21-62 (2007 (Pubitemid 44881193)
25. Helleman, J., Jansen, M. P., Burger, C., van Der Burg, M. E. & Berns, E. M. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int. J. Biochem. Cell Biol. 42, 25-30 (2010
26. Tothill, R. W. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198 (2008
27. Allred, D. C., Harvey, J. M., Berardo, M. & Clark, G. M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11, 155-168 (1998 (Pubitemid 28144151)
28. Marchini, S. et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 49, 520-530 (2012
29. Baldwin, R. L., Tran, H. & Karlan, B. Y. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res. 63, 1413-1419 (2003 (Pubitemid 36348725)
30. Yamamura, S. et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int. J. Cancer 130, 20-28 (2012
31. Do, T. V., Kubba, L. A., Du, H., Sturgis, C. D. & Woodruff, T. K. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol. Cancer Res. 6, 695-705 (2008
32. Cao, L. et al. Tissue transglutaminase links TGF-b, epithelial to mesenchymal transition and stem cell phenotype in ovarian cancer. Oncogene 31, 2521-2534 (2012
33. Henriksen, R. et al. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab. Invest. 73, 213-220 (1995
34. Smith, A. L. et al. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 31, 5162-5171 (2012
35. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341-347 (2010
36. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008 (Pubitemid 351627379)
37. Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D. & Lopes, C. S. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann. Oncol. 15, 1535-1542 (2004 (Pubitemid 39409745)
38. Darai, E. et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors. Hum. Pathol. 28, 922-928 (1997 (Pubitemid 27355552)
39. Quattrocchi, L., Green, A. R., Martin, S., Durrant, L. & Deen, S. The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch. 459, 21-29 (2011
40. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005 (Pubitemid 40839735)
41. Baccarini, A. & Brown, B. D. Monitoring microRNA activity and validating microRNA targets by reporter-based approaches. Methods Mol. Biol. 667, 215-233 (2010